Unilink Pharma Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
as on 17-06-2024
- Paid Up Capital ₹ 1.60 Cr
as on 17-06-2024
- Company Age 19 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 22.84 Cr
as on 17-06-2024
- Revenue 13.87%
(FY 2023)
- Profit -4.66%
(FY 2023)
- Ebitda -21.75%
(FY 2023)
- Net Worth 12.29%
(FY 2023)
- Total Assets 18.84%
(FY 2023)
About Unilink Pharma
The Corporate was formerly known as Unilink Drugs And Pharmaceuticals Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 1.60 Cr.
The company currently has active open charges totaling ₹22.84 Cr.
Sreenivasan Karunakaran and Karunakaran Vijaya serve as directors at the Company.
- CIN/LLPIN
U24232TN2005PTC055459
- Company No.
055459
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
23 Feb 2005
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai-600017., Tamil Nadu, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Unilink Pharma Private Limited offer?
Unilink Pharma Private Limited offers a wide range of products and services, including Organic and Inorganic Solvents, Alcohol Solvents, Dimethylaminoethanol DMAE.
Who are the key members and board of directors at Unilink Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Karunakaran Vijaya  | Managing Director | 23-Feb-2005 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sreenivasan Karunakaran | Whole-Time Director | 02-Oct-2009 | Current |
Financial Performance of Unilink Pharma.
Unilink Pharma Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 13.87% increase. The company also saw a slight decrease in profitability, with a 4.66% decrease in profit. The company's net worth Soared by an impressive increase of 12.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Unilink Pharma?
In 2023, Unilink Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 30 May 2020 | ₹1.97 Cr | Open |
Others Creation Date: 08 Jan 2020 | ₹3.00 Cr | Open |
Icici Bank Limited Creation Date: 19 Mar 2014 | ₹1.40 Cr | Open |
How Many Employees Work at Unilink Pharma?
Unlock and access historical data on people associated with Unilink Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Unilink Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Unilink Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
